Your browser doesn't support javascript.
No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study.
Atmaca, A; Demirci, I; Haymana, C; Tasci, I; Sahin, I; Cakal, E; Ata, N; Dagdelen, S; Salman, S; Emral, R; Sahin, M; Celik, O; Demir, T; Ertugrul, D; Unluturk, U; Caglayan, M; Satman, I; Sonmez, A.
  • Atmaca A; Department of Endocrinology and Metabolism, School of Medicine, Samsun Ondokuz Mayis University, Samsun, Turkey. atmaca_aysegul@yahoo.com.
  • Demirci I; Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.
  • Haymana C; Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.
  • Tasci I; Department of Internal Medicine Gulhane School of Medicine and Gulhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.
  • Sahin I; Department of Endocrinology and Metabolism, School of Medicine, Malatya Inonu University, Malatya, Turkey.
  • Cakal E; Department of Endocrinology and Metabolism, School of Medicine, Diskapi Yildirim Beyazit Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.
  • Ata N; Department of Strategy Development, Ministry of Health, Republic of Turkey, Ankara, Turkey.
  • Dagdelen S; Department of Endocrinology and Metabolism, School of Medicine, Hacettepe University, Ankara, Turkey.
  • Salman S; Department of Endocrinology and Metabolism, Medica Clinic, Istanbul, Turkey.
  • Emral R; Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.
  • Sahin M; Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.
  • Celik O; Public Hospitals General Directorate, Ministry of Health, Republic of Turkey, Ankara, Turkey.
  • Demir T; Department of Endocrinology and Metabolism, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
  • Ertugrul D; Department of Endocrinology and Metabolism, Kecioren Training and Research Hospital, School of Medicine, University of Health Sciences Turkey, Ankara, Turkey.
  • Unluturk U; Department of Endocrinology and Metabolism, School of Medicine, Hacettepe University, Ankara, Turkey.
  • Caglayan M; Ankara Provincial Health Directorate, Ankara, Turkey.
  • Satman I; Department of Endocrinology and Metabolism, School of Medicine, Istanbul University, Istanbul, Turkey.
  • Sonmez A; Turkish Institute of Public Health and Chronic Diseases, Istanbul, Turkey.
Osteoporos Int ; 33(1): 273-282, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1359937
ABSTRACT
This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection.

INTRODUCTION:

Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women.

METHODS:

Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Turkish Ministry of Health Database. Women 50 years or older with confirmed COVID-19 who were receiving anti-osteoporosis drugs were compared with a 11 propensity score-matched COVID-19 positive women who were not receiving these drugs. The primary outcomes were hospitalization, ICU (intensive care unit) admission, and mortality.

RESULTS:

A total of 1997 women on anti-osteoporosis drugs and 1997 control patients were analyzed. In the treatment group, 1787 (89.5%) women were receiving bisphosphonates, 197 (9.9%) denosumab, and 17 (0.9%) teriparatide for the last 12 months. Hospitalization and mortality rates were similar between the treatment and control groups. ICU admission rate was lower in the treatment group (23.0% vs 27.0%, p = 0.013). However, multivariate analysis showed that anti-osteoporosis drug use was not an independent associate of any outcome. Hospitalization, ICU admission, and mortality rates were similar among bisphosphonate, denosumab, or teriparatide users.

CONCLUSION:

Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Osteoporosis / Pharmaceutical Preparations / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans Language: English Journal: Osteoporos Int Journal subject: Metabolism / Orthopedics Year: 2022 Document Type: Article Affiliation country: S00198-021-06067-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Osteoporosis / Pharmaceutical Preparations / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans Language: English Journal: Osteoporos Int Journal subject: Metabolism / Orthopedics Year: 2022 Document Type: Article Affiliation country: S00198-021-06067-2